Latest Content

In today's Pharmaceutical Executive Daily, Bayer agrees to acquire Perfuse Therapeutics for up to $2.45 billion and Madrigal obtains an exclusive global license for a precision siRNA therapy targeting a key genetic driver of MASH, Zentalis Pharmaceuticals announces the first patient dosed in a Phase III trial and Brooke Ervin argues that translating real-world evidence into commercial and clinical impact in urology requires more than access to data.

Zentails announced the first dosage of Azenosertib administered in its phase III Aspenova trial to test azenosertib vs chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer.

Madrigal and Bayer strike billion-dollar deals to expand pipelines, with Madrigal licensing a PNPLA3-targeting siRNA for MASH and Bayer acquiring Perfuse Therapeutics to strengthen its ophthalmology portfolio.

Getting from insight to impact requires more than access to information.

Aradigm Health’s CEO discusses how payers and other entities in the healthcare ecosystem are developing strategies to ensure cell & gene therapy costs don’t prevent patients from accessing them.

In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech releases its first quarter 2026 financial results, and Peter Harbin argues that biopharma's longstanding deciling-based sales targeting model is overdue for a fundamental rethink.

FDA clears Cellenkos’ IND for CK0802, enabling a mid-stage trial in steroid-refractory GVHD.

BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company accelerates its oncology investments and restructures its manufacturing footprint.

Why biopharma's targeting model is overdue for evolution.

Data-driven decision-making, evolving access models, and accelerating adoption of AI create a complex commercialization landscape.

In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentary by Jeremy Richardson argues that MFN pricing and shifting policy expectations are making affordable direct-to-patient programs at scale an operational necessity rather than a strategic option, and a new article examines how a customer-based process can synchronize sales and marketing organizations for competitive advantage in pharma.

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager cizutamig to expand its immunology pipeline.

Policy changes like Most-Favored Nation (MFN) Pricing are creating new operational requirements for pharmaceutical companies to prove every dollar delivers value.